Program

The Best of ASCO Program presents the scientific and educational highlights of the ASCO Annual Meeting selected from the year’s notable abstracts.

Saturday

7:00 AM- 2:30 PM Exhibits Open
7:00 AM-8:00 AM Complimentary Continental Breakfast
8:00 AM-9:40 AM

Lung Cancer

Alexander Chi, MD
Marshfield Clinic- Eau Claire Oncology
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/ Thoracic Cancers

Abstract 8502: Pragmatic Study of a Lymph Node (LN) Collection Kit for Non-Small Cell Lung Cancer (NSCLC) Resection. (Raymond Osarogiagbon)

Abstract 8503: DREAM: A Phase II study of DuRvalumab with first line chEmotherApy in Mesothelioma: First Results.(Anna Nowak)

Abstract 8506: Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. (Hyun Chung)

Abstract 8507: Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: results from the Phase 2 TRINITY study. (David Carbone)


Shirish M. Gadgeel, MD
University of Michigan
Lung Cancer—Non-Small Cell Metastatic

Abstract LBA4: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. (Gilberto Lopes)

Abstract 105: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel with pembrolizumab or placebo for patients with metastatic squamous non-small cell lung cancer (NSCLC). (Luis Paz-Ares)

Abstract LBA9000: IMpower131: Primary PFS and Safety Analysis of a Randomized Phase III Study of Atezolizumab + Carboplatin + Paclitaxel or Nab-Paclitaxel vs Carboplatin + nab-Paclitaxel as 1L Therapy in Advanced Squamous NSCLC. (Robert Jotte)

Abstract 9001: Nivolumab (nivo) + ipilimumab (ipi) vs chemotherapy as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): additional endpoints from the randomized phase 3 CheckMate 227 study. (Hossein Borghaei)

Abstract 9006: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations. NEJ026. (Naoki Furuya)

Panel Question and Answer

9:40 AM-10:00 AM Break
10:00 AM-10:45 AM

Head and Neck Cancer

Mark Agulnik, MD
Northwestern University
Head and Neck Cancer

Abstract 6000: Results of a randomized phase III study of Nimotuzumab in combination with concurrent radiotherapy and Cisplatin versus radiotherapy and Cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck. (Vijay Patil)

Abstract 6006: Results of a randomized, placebo (PBO) controlled, double-blind P2b trial of GC4419 (avisopasem manganese) to reduce duration, incidence and severity and delay onset of severe radiation-related oral mucositis (SOM) in patients (pts) with locally advanced squamous cell cancer of the oral cavity (OC) or oropharynx (OP).(Carryn Anderson)

Abstract 6008: Multicenter Phase II Trial of Palbociclib, a Selective Cyclin Dependent Kinase (CDK) 4/6 Inhibitor, and Cetuximab in Platinum-Resistant HPV Unrelated (-) Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC). (Douglas Adkins)

Abstract 6009: A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC). (Sean McBride)

Question and Answer

10:45 AM-11:30 AM

Gynecologic Cancer

Rebecca Stone, MD, MS
Johns Hopkins Medical Center
Gynecologic Cancer

Abstract 5500: Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602. (Takashi ONDA)

Abstract 5505: Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study. (Martee Hensley)

Abstract 5506: Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. (Sandro Pignata)

Abstract 5508: Cost-Effectiveness of Maintenance Therapy in Advanced Ovarian Cancer: Paclitaxel, Bevacizumab, Niraparib, Rucaparib, Olaparib, and Pembrolizumab. (Juliet Wolford)

Question and Answer

11:30 AM-12:30 PM Complimentary Boxed Lunch
12:30 PM-2:10 PM

Melanoma/Skin Cancers and Developmental Therapeutics

Jeffrey A. Sosman, MD
Northwestern University
Melanoma/Skin Cancers
 

Abstract 108: Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study. (Georgina Long)

 

Abstract 9501: Final analysis of DECOG-SLT trial: No survival benefit for complete lymph node dissection in melanoma patients with positive sentinel node. (Ulrike Leiter)

 

Abstract 9502: Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). (Jeffrey Weber)

 

Abstract 9504: Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma. (Reinhard Dummer)



Laura W. Goff, MD
Vanderbilt University Medical Center
Developmental Therapeutics
 

Abstract 102: A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. (Alexander Drilon)

 

Abstract 3000: ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers. (Timothy Yap)

 

Abstract 3003: Durability of Response in ZUMA-1, the Pivotal Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Refractory Large B Cell Lymphoma. (Frederick Locke)

 

Abstract 3006: NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT. (Adi Diab)



Panel Question and Answer

2:10 PM-2:30 PM Break
2:30 PM-4:10 PM

Gastrointestinal Cancers

Wells A. Messersmith, MD, FACP
University of Colorado Comprehensive Cancer Center
Gastrointestinal (Colorectal) Cancer
 

Abstract 3501: Long-term results of the ADORE trial: adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer. (Yong Sang Hong)

 

Abstract LBA3503: A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. (François Quenet)

 

Abstract 3505: First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. (Filippo Pietrantonio)

 

Abstract 3514: KEYNOTE-164: Pembrolizumab for Patients With Advanced Microsatellite Instability High (MSI-H) Colorectal Cancer. (Dung Le)



E. Gabriela Chiorean, MD
University of Washington
Gastrointestinal (Noncolorectal) Cancer
 

Abstract LBA4001: Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized controlled phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. (Thierry Conroy)

 

Abstract 4004: A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). (Pamela Kunz)

 

Abstract LBA4008: Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial. (Janusz Jankowski)

 

Abstract 4019: Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial. (Ghassan Abou-Alfa)



Panel Question and Answer